EP Patent

EP2299987B1 — Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Assigned to Boehringer Ingelheim International GmbH · Expires 2018-02-21 · 8y expired

What this patent protects

Patent listed against nintedanib-esylate.

Drugs covered by this patent

nintedanib-esylate (NINTEDANIB ESYLATE)

Patent Metadata

Patent number: EP2299987B1
Jurisdiction: EP
Classification: —
Expires: 2018-02-21
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.